



OPEN ACCESS

EDITED AND REVIEWED BY

Joy Perrier,
Neuropsychologie et Imagerie de la Mémoire
Humaine, France

*CORRESPONDENCE

Sonia Ancoli-Israel
✉ sancoliisrael@health.ucsd.edu

RECEIVED 15 February 2024

ACCEPTED 01 July 2024

PUBLISHED 03 October 2024

CITATION

Rissling M, Liu L, Youngstedt SD,
Trofimenko V, Natarajan L, Neikrug AB,
Jeste N, Parker BA and Ancoli-Israel S (2024)
Corrigendum: Preventing sleep disruption
with bright light therapy during chemotherapy
for breast cancer: a phase II randomized
controlled trial. *Front. Neurosci.* 18:1386314.
doi: 10.3389/fnins.2024.1386314

COPYRIGHT

© 2024 Rissling, Liu, Youngstedt, Trofimenko,
Natarajan, Neikrug, Jeste, Parker and
Ancoli-Israel. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Preventing sleep disruption with bright light therapy during chemotherapy for breast cancer: a phase II randomized controlled trial

Michelle Rissling¹, Lianqi Liu², Shawn D. Youngstedt³,
Vera Trofimenko⁴, Loki Natarajan^{5,6}, Ariel B. Neikrug⁷,
Neelum Jeste⁸, Barbara A. Parker^{2,6} and Sonia Ancoli-Israel^{1,6*}

¹Department of Psychiatry, University of California, San Diego, San Diego, CA, United States, ²Department of Medicine, University of California, San Diego, San Diego, CA, United States, ³Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, United States, ⁴St. Joseph Hospital, Orange, CA, United States, ⁵Family Medicine and Public Health, University of California, San Diego, San Diego, CA, United States, ⁶Moore's Cancer Center, University of California, San Diego, San Diego, CA, United States, ⁷Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, United States, ⁸Johnson & Johnson, San Diego, CA, United States

KEYWORDS

breast cancer, light therapy, sleep, actigraphy, PSQI, activity

A Corrigendum on

[Preventing sleep disruption with bright light therapy during chemotherapy for breast cancer: a phase II randomized controlled trial](#)

by Rissling, M., Liu, L., Youngstedt, S. D., Trofimenko, V., Natarajan, L., Neikrug, A. B., Jeste, N., Parker, B. A., and Ancoli-Israel, S. (2022). *Front. Neurosci.* 16:815872. doi: 10.3389/fnins.2022.815872

In the published article, there was an error in [Table 2](#) as published. The sample size numbers were reversed. The Bright White Light Group sample size numbers in the original table were really the sample sizes for the Dim Red Light group, and visa versa. The correct sample size numbers appear in the corrected table. The corrected [Table 2](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 2 Mean (SE) PSQI total and component scores by group condition and mixed model analysis.

PSQI	Bright white light					Dim red light				
	Baseline N = 22	C1TW N = 17	C1RW N = 18	C4TW N = 16	C4RW N = 15	Baseline N = 16	C1TW N = 14	C1RW N = 13	C4TW N = 14	C4RW N = 14
Global	8.9 (0.9)	9.1 (0.8)	8.6 (1.0)	8.5 (0.9)	6.9 (0.9)	7.9 (0.9)	8.1 (1.1)	7.1 (1.3)	7.9 (0.9)	6.9 (1.1)
Subjective sleep quality	1.3 (0.2)	1.4 (0.2)	1.0 (0.2)	0.9 (0.2)	0.4** (0.1)	1.6 (0.2)	1.4 (0.3)	1.0* (0.3)	1.1 (0.2)	0.9* (0.2)
Sleep latency	1.4 (0.2)	1.4 (0.2)	1.4 (0.2)	0.9 (0.3)	0.8 (0.3)	1.5 (0.3)	1.1 (0.3)	1.2 (0.3)	1.0 (0.3)	1.3 (0.3)
Sleep duration	1.3 (0.2)	0.9 (0.2)	0.9 (0.2)	0.9 (0.2)	0.9* (0.2)	0.8 (0.1)	0.8 (0.2)	0.5 (0.2)	0.4 (0.2)	0.5 (0.1)
Habitual sleep efficiency	1.8 (0.3)	1.9 (0.3)	1.3 (0.3)	1.6 (0.3)	1.1 (0.3)	1.3 (0.3)	0.9 (0.3)	0.9 (0.3)	1.2 (0.4)	0.7 (0.3)
Sleep disturbances	1.5 (0.1)	1.4 (0.2)	1.2 (0.1)	1.3 (0.2)	1.1* (0.2)	1.6 (0.1)	1.5 (0.2)	1.4 (0.1)	1.7 (0.2)	1.5 (0.1)
Use of sleeping medication	1.1 (0.3)	1.4 (0.4)	1.7 (0.3)	1.8 (0.4)	1.6 (0.4)	0.7 (0.3)	1.5* (0.4)	1.3 (0.4)	1.4* (0.4)	1.2 (0.4)
Daytime dysfunction	0.6 (0.2)	0.8 (0.2)	0.9 (0.2)	1.1* (0.1)	1.0* (0.2)	0.6 (0.2)	0.9 (0.2)	0.7 (0.2)	1.0 (0.2)	0.8 (0.2)

Compared to Baseline in each group: *p < 0.05, **p < 0.01; there were no significant group by time interaction for both groups at any time point (all p's > 0.1).